FDA Brief

Warning letters Drugs

FDA warning letter to

Jose M. Carpio, M.D.

MediumIssued May 28Posted Jun 9Center for Drug Evaluation and Research (CDER)

FDA warned clinical investigator Dr. Jose Carpio of Miami Lakes, FL, that trial subjects received less than the protocol-required dose of study drug.

What happened

FDA inspected Dr. Carpio's clinical site between May 1 and May 13, 2025, as part of its Bioresearch Monitoring Program, which checks how human research is conducted. The agency found that three subjects in an outpatient group of one study were given study drug or control product only on Day 1, and not at their Day 2 and Day 4 visits, so they took less than the five-day dose the study plan required. FDA reviewed his June 3, 2025 response and called it inadequate because it did not give enough detail on how he would oversee study procedures going forward.

What FDA found

  1. Dr. Carpio did not make sure the study was run the way the study plan (the protocol, the written plan for the trial) required.

    21 CFR 312.60
  2. Three outpatient subjects were given study drug only on Day 1 instead of on Days 1, 2 and 4, so they took less than the required five-day dose.

    21 CFR 312.60

What FDA wants

FDA asks Dr. Carpio to write back within 15 business days of receiving the letter describing what he has done to prevent similar violations, including details on how his new standard operating procedure will be carried out. The reply should go by email to CDER-OSI-Communications@fda.hhs.gov.

Who should pay attention

  • sponsors and contract research organizations running multi-site drug trials
  • other clinical investigators and site research staff
  • institutional review boards that oversee trial sites

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Bertrand P. Cole, D.O.

    FDA warns Dr. Bertrand P. Cole that he gave four trial subjects too much drug by not following the study plan.

    High risk
  2. Purushothaman Damodara Kumaran, M.D. / Senthil Specialty Hospital

    FDA warned Senthil Specialty Hospital and Dr. Purushothaman Damodara Kumaran about missed safety monitoring in a bioequivalence study of an investigational drug.

    High risk
  3. Devalingam Mahalingam, M.D., Ph.D.

    FDA warns clinical investigator Devalingam Mahalingam, M.D., Ph.D. over a 100-fold investigational drug overdose that led to a subject's death.

    High risk